JPS63190833A

Method and composition for orally administrating physiological substance to animals

Abstract

(57) [Abstract] Since this gazette is application data in front of an electronic application, the data of an abstract is not recorded.

Term

Term ended

Projected expiry passed 23 October 2007, 18.9 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

29 claims: 29 independent, 0 dependent

  1. 1
    [Claim(s)] 【特許請求の範囲】 1、(a)生理活性物質の有効量を生分解性で生体無毒性の賦型剤でカプセル化して、動物の胃腸経路を分解することなくもしくは最小限の分解で通過して“ペイヤーパツチ”で吸収され得るような寸法のマイクロカプセルに成型し、次いで (b)このマイクロカプセルの必要量を動物に経口投与する ことを特徴とする動物の“ペイヤーパツチ”に生理活性物質を経口投与する方法。 An effective amount of 1 and the (a) physiologically active substance is encapsulated by an allocated type agent of living body avirulence by biodegradability, Without decomposing a gastroenteric course of an animal, it passes by the minimum decomposition and molds into a microcapsule of a size which may be absorbed by "pay Ya Potch", subsequently, (b) -- a method of administering a physiologically active substance orally to "pay Ya Potch" of an animal administering necessary quantity of this microcapsule orally to an animal.
  2. 2
    2、直径が10μm以下でる特許請求の範囲第1項記載の方法。 A method of an application for patent out of which 2 and 10 micrometers or less of diameters come given in the 1st paragraph of a range.
  3. 3
    3、直径が5μm以下である特許請求の範囲第1項記載の方法。 A way of an application for patent given in the 1st paragraph of a range 3 and a diameter are 5 micrometers or less.
  4. 4
    4、直径が3μm以下である特許請求の範囲第1項記載の方法。 A way of an application for patent given in the 1st paragraph of a range 4 and a diameter are 3 micrometers or less.
  5. 5
    5、賦型剤が重合体である特許請求の範囲第1項記載の方法。 A way of an application for patent given in the 1st paragraph of a range 5 and an allocated type agent are polymers.
  6. 6
    6、賦型剤が共重合体である特許請求の範囲第1項記載の方法。 A way of an application for patent given in the 1st paragraph of a range 6 and an allocated type agent are copolymers.
  7. 7
    7 and an allocated type agent are poly (glycolic acid) and a mixed copolymer of DL-lactide and glycolide, A method of an application for patent chosen from a group which consists of copoly oxalate, polycaprolactone, poly (lactide Co-Power pro lactone), poly (ester amide), poly Ortho ester, and poly (beta-hydro-Oxy butanoic acid) given in the 1st paragraph of a range. 7、賦型剤がポリ(グリコール酸)、DL-ラクチドとグリコライドの混合共重合体、コポリオキザレート、ポリカプロラクトン、ポリ(ラクチド-コ-カプロラクトン)、ポリ (エステルアミド)、ポリオルソエステル及びポリ(β-ハイドロオキシ酪酸)よりなる群から選ばれる特許請求の範囲第1項記載の方法。
  8. 8
    8、コポリマー賦型剤がポリ(DL-ラクチド-コ-グリコライド)である特許請求の範囲第1項記載の方法。 A way of an application for patent given in the 1st paragraph of a range 8 and a copolymer Chinese poem type agent are poly(DL-Lactide-co-glycolide).
  9. 9
    9、コポリマー賦型剤のラクチドとグリコライドのモル比が45:65乃至90:10である特許請求の範囲第8項記載の方法。 A way of an application for patent given in the 8th paragraph of a range lactide of 9 and a copolymer Chinese poem type agent and a molar ratio of glycolide are 45:65 thru/or 90:10.
  10. 10
    10、生理活性物質が抗原である特許請求の範囲第1項記載の方法。 A way of an application for patent given in the 1st paragraph of a range 10 and a physiologically active substance are antigens.
  11. 11
    11、抗原がトリニトロフエニルキイホールリムペツトヘモシアニンである特許請求の範囲第10項記載の方法。 A way of an application for patent given in the 10th paragraph of a range 11 and an antigen are trinitro phenyl Keyhole rim pett hemocyanin.
  12. 12
    12、マイクロカプセルの直径が1~5μmで、生理活性物質がトリニトロフエニルキイホールリムペツトヘモシアニンであり、賦型剤が50:50ポリ(DL-ラクチド-コ-グリコライド)である特許請求の範囲第11項記載の方法。 A way of an application for patent given in the 11th paragraph of a range a physiologically active substance is [ a diameter of 12 and a microcapsule ] trinitro phenyl Keyhole rim pett hemocyanin in 1~5 micrometers, and an allocated type agent is 50:50 poly(DL-Lactide-co-glycolide).
  13. 13
    13、生理活性物質がトクソイドである特許請求の範囲第1項記載の方法。 A way of an application for patent given in the 1st paragraph of a range 13 and a physiologically active substance are Toxoids.
  14. 14
    14、トクソイドがスタフイロコカルエントロトキシンである特許請求の範囲第13項記載の方法。 A way of an application for patent given in the 13th paragraph of a range 14 and Toxoid are staph iroko Carlentro toxin.
  15. 15
    15、有効量の生理活性物質を生分解性かつ生体分解性の賦型剤中にカプセル化し、分解することなく胃腸経路を通過して“ペイヤーパツチ”に吸収され得る寸法としたことを特徴とする動物の“ペイヤーパツチ”がに生理活性物質を経口投与するための組成物。 a constituent for encapsulating 15 and an effective amount of physiologically active substances in an allocated type agent of biodegradability and living body resolvability, and passing a gastroenteric course, and "pay Ya Potch" of an animal considering it as a size which may be absorbed by "pay Ya Potch" being alike, and administering a physiologically active substance orally, without decomposing.
  16. 16
    16、第1及び第2共重合体賦型剤が異なつた共重合体比を有する特許請求の範囲第15項記載の組成物。 A constituent of an application for patent given in the 15th paragraph of a range in which 16 and the 1st and 2nd copolymer Chinese poem type agent have a different Noodle copolymer ratio.
  17. 17
    17、マイクロカプセルの直径が10μm以下である特許請求の範囲第16項記載の組成物。 A constituent of an application for patent 17 and given in the 16th paragraph of a range a given diameter of a microcapsule is 10 micrometers or less.
  18. 18
    18、マイクロカプセルの直径が5μm以下である特許請求の範囲第17項記載の組成物。 A constituent of an application for patent 18 and given in the 17th paragraph of a range a given diameter of a microcapsule is 5 micrometers or less.
  19. 19
    19、マイクロカプセルの直径が3μm以下である特許請求の範囲第17項記載の組成物。 A constituent of an application for patent 19 and given in the 17th paragraph of a range a given diameter of a microcapsule is 3 micrometers or less.
  20. 20
    20、賦型剤が重合体である特許請求の範囲第19項記載の組成物。 A constituent of an application for patent whose 20 and allocated type agent are polymers given in the 19th paragraph of a range.
  21. 21
    21、賦型剤が共重合体である特許請求の範囲第20項記載の組成物。 A constituent of an application for patent whose 21 and allocated type agent are copolymers given in the 20th paragraph of a range.
  22. 22
    22 and an allocated type agent are poly (glycolic acid) and a mixed copolymer of DL-lactide and glycolide, A constituent of an application for patent given in the 21st paragraph of a range chosen from a group which consists of copoly oxalate, polycaprolactone, poly (lactide Co-Power pro lactone), poly (ester amide), poly Ortho ester, and poly (beta-hydro-Oxy butanoic acid). 22、賦型剤がポリ(グリコール酸)、DL-ラクチドとグリコライドの混合共重合体、コポリオキザレート、ポリカプロラクトン、ポリ(ラクチド-コ-カプロラクトン)、ポリ(エステルアミド)、ポリオルソエステル及びポリ(β-ハイドロオキシ酪酸)よりなる群から選ばれる特許請求の範囲第21項記載の組成物。
  23. 23
    23、共重合体賦型剤がポリ(DL-ラクチド-コ-グリコライド)である特許請求の範囲第22項記載の組成物。 A constituent of an application for patent whose 23 and copolymer Chinese poem type agent are poly(DL-Lactide-co-glycolide) given in the 22nd paragraph of a range.
  24. 24
    24、共重合体賦型剤のラクチド対グリコライドのモル比が50:50乃至90:10である特許請求の範囲第23項記載の組成物。 A constituent of an application for patent whose molar ratios of lactide versus glycolide of 24 and a copolymer Chinese poem type agent are 50:50 thru/or 90:10 given in the 23rd paragraph of a range.
  25. 25
    25、生理活性物質の少くも一種が原生動物、ビールス、菌類、バクテリア抗原である特許請求の範囲第15項記載の組成物。 A constituent of an application for patent 25 and given in the 15th paragraph of a range there are also few physiologically active substances and given kinds are a protozoan, a virus, fungi, and a bacteria antigen.
  26. 26
    26、抗原がトリニトロフエニルキイホールリムペツトヘモシアニンである特許請求の範囲第25項記載の組成物。 A constituent of an application for patent whose 26 and antigen are trinitro phenyl Keyhole rim pett hemocyanin given in the 25th paragraph of a range.
  27. 27
    27、マイクロカプセルの直径が1~5μmで、生理活性物質がトリニトロフエニルキイホールリムペツトヘモシアニンであり、賦型剤が50:50ポリ(DL-ラクチド-コ-グリコライド)である特許請求の範囲第26項記載の組成物。 A constituent of an application for patent whose physiologically active substance a diameter of 27 and a microcapsule is trinitro phenyl Keyhole rim pett hemocyanin in 1~5 micrometers and whose allocated type agent is 50:50 poly(DL-Lactide-co-glycolide) given in the 26th paragraph of a range.
  28. 28
    28、生理活性物質がトクソイドである特許請求の範囲第15項記載の組成物。 A constituent of an application for patent whose 28 and physiologically active substance are Toxoids given in the 15th paragraph of a range.
  29. 29
    29、トクソイドがスタフイロコカルエントロトキシンである特許請求の範囲第28項記載の組成物。 A constituent of an application for patent whose 29 and Toxoid are staph iroko Carlentro toxin given in the 28th paragraph of a range.
Independent claims29